Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05625529 · ClinicalTrials.gov registry record
ExoLuminate Study for Early Detection of Pancreatic Cancer
A clinical trial of Pancreas Cancer and Pancreatic Neoplasms, sponsored by Biological Dynamics.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT05625529 is a study of Pancreas Cancer and Pancreatic Neoplasms that is actively recruiting participants, run by Biological Dynamics. The registered enrollment target is 1,000 participants, above the 889-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (12% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05625529, a study of Pancreas Cancer and Pancreatic Neoplasms, is actively recruiting participants, sponsored by Biological Dynamics.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC). Those with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, and a personal or family history of pancreatitis. The goal of the study is to compare the performance of ExoVerita™ assay in early detection of PDAC to current standard-of-care methods of surveillance.
Conditions Studied
Study Locations (1)
California
- Biological Dynamics - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2022-12-19 |
| Est. Completion | 2028-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05625529
The ClinicalTrials.gov registry entry for NCT05625529 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 889-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (12% higher). The listed sponsor is Biological Dynamics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Pancreas Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT05625529 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05625529 about?
NCT05625529 is a clinical study titled "ExoLuminate Study for Early Detection of Pancreatic Cancer". ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC). Those with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, f...
What is the current status of trial NCT05625529?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2022-12-19. Estimated completion is 2028-01-01.
What conditions does trial NCT05625529 study?
This clinical trial studies the following conditions: Pancreas Cancer, Pancreatic Neoplasms, Exosomes, Extracellular Vesicles.
Who is sponsoring clinical trial NCT05625529?
This trial is sponsored by Biological Dynamics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05625529 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
RECRUITING
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
The Cancer of the Pancreas Screening-5 CAPS5)Study
RECRUITING · Phase 3
-
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.